Bispecific Antibodies Close in on Cancer
Plotting Molecular Pincer Movements, Denying Cancer Room to Maneuver
Resolving Nonspecific Binding, Regeneration and Other Problems
Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
<i>Prometheus v. Mayo</i>
The U.S. Supreme Court hears oral arguments on December 7 in a case closely watched by molecular diagnostics companies seeking guidance about what intellectual property they can and cannot patent. Mayo Collaborative Services (doing business as Mayo Medical Laboratories) and Mayo Clinic Rochester have urged the justices to overturn a decision by the Court of Appeals for the Federal Circuit last December upholding two diagnostic method patents owned by Prometheus Laboratories. At issue in Prometheus Laboratories, Inc. v. Mayo Collaborative Services are patents covering the methods of dosage calibration for thiopurine drugs for gastrointestinal and nongastrointestinal autoimmune diseases. The methods were designed to account for the context of a treatment regimen based on the individual patient’s metabolism. Will the justices side with Prometheus or Mayo?